[1] LIN YJ,ANZAGHE M,SCHULKE S,et al.Update on the pathomechanism,diagnosis,and treatment options for rheumatoid arthritis[J].Cells,2020,9(4):880.
[2] CUSH JJ.Rheumatoid arthritis:early diagnosis and treat-ment[J].Med Clin North Am,2021,105(2):355-365.
[3] 王磊,姚宏伟.阿达木单抗治疗类风湿关节炎有效性和安全性的系统评价[J].山西医药杂志,2021,50(15):2316-2318.
[4] 张洲,王秀丽,赵成广,等.阿达木单抗治疗幼年特发性关节炎的疗效分析[J].中国医科大学学报,2022,51(8):756-759.
[5] 《生物制剂治疗类风湿关节炎合理用药中国专家共识》编写专家组.生物制剂治疗类风湿关节炎合理用药中国专家共识[J].中国新药杂志,2022,31(21):2174-2184.
[6] 张伟,郭慧娟,吴系美,等.血清sST2在类风湿性关节炎病情及疗效监测中的价值[J].检验医学,2021,36(12):1238-1242.
[7] 王欣彤,周朝波,杨丽晖,等.个性化神经肌训练对膝关节骨关节炎患者膝关节功能,疼痛,僵硬症状,生活质量的影响研究[J].河北医科大学学报,2021,42(4):395-400.
[8] SMOLEN JS,LANDEWE RBM,BIJLSMA JWJ,et al.Eular recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs:2019 update[J].Ann Rheum Dis,2020,79(6):685-699.
[9] GUADAGNIN DA,MAZZALI LV,SKARE TL,et al.Treating rheumatoid arthritis with leflunomide monotherapy versus combination therapy with methotrexate[J].Eur J Rheumatol,2021,8(1):12-15.
[10] 徐连那,李旭艳,庞琳娜,等.甲氨蝶呤联合来氟米特治疗类风湿性关节炎对血清疼痛介质以及Th1/Th2型细胞因子的影响[J].热带医学杂志,2022,22(7):983-986,1009.
[11] WU J,FENG Z,CHEN L,et al.Tnf antagonist sensitizes synovial fibroblasts to ferroptotic cell death in collagen-induced arthritis mouse models[J].Nat Commun,2022,13(1):676.
[12] BALANESCU AR,CITERA G,PASCUAL-RAMOS V,et al.Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors:results from the open-label,randomised controlled ORAL Sur-veillance trial[J].Ann Rheum Dis,2022,81(11):1491-1503.
[13] 邹鹏,程叶,金宝,等.甲氨蝶呤与阿达木单抗联合治疗对类风湿关节炎患者关节症状及血清抗CCP抗体,炎症因子水平的影响[J].武警后勤学院学报:医学版,2021,30(9):90-91,94.
[14] WANG R,DADGUPTA A,WARD MM,et al.Predicting probability of response to tumor necrosis factor inhibitors for individual patients with ankylosing spondylitis[J].JAMA Netw Open,2022,5(3):e222312. |
2025, Vol. 45 
